Jabbour Highlights New Data With Asciminib and Ponatinib in CML

Dr Jabbour discusses updates from the 2021 ASH Annual Meeting and Exposition in chronic myeloid leukemia, including findings from the phase 3 ASCEMBL trial evaluating asciminib vs bosutinib and data with ponatinib from a post-hoc analysis of the phase 2 OPTIC trial.

Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored in part by Takeda, we had the pleasure of hearing from Elias Jabbour, MD, a professor in the Department of Leukemia and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. Dr Jabbour joined us to discuss updates from the 2021 ASH Annual Meeting and Exposition in chronic myeloid leukemia (CML), including findings from the phase 3 ASCEMBL trial (NCT03106779) evaluating asciminib (Scemblix) vs bosutinib (Bosulif) and data with ponatinib (Iclusig) from a post hoc analysis of the phase 2 OPTIC trial (NCT02467270).

In October 2021, the FDA granted an accelerated approval to asciminib for the treatment of patients with Philadelphia chromosome (Ph)–positive CML in chronic phase who were previously treated with at least 2 TKIs. The agent also received full approval for patients with Ph-positive CML in any phase who present with a T315I mutation. Ponatinib is approved for the same indications.

In this episode, Dr Jabbour reviewed new data with asciminib and ponatinib in the post–second generation TKI setting.

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, sponsored in part by Takeda. Check back on Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
View All
Related Content